London
· Delayed Price · Currency is GBP · Price in DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of GBP 3.29 billion. The enterprise value is 2.30 billion.
| Market Cap | 3.29B |
| Enterprise Value | 2.30B |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.40% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 60.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 473.61 |
| PB Ratio | 3.45 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.22 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -22.04 |
Financial Position
The company has a current ratio of 21.14, with a Debt / Equity ratio of 0.05.
| Current Ratio | 21.14 |
| Quick Ratio | 21.11 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.42 |
| Interest Coverage | -37.27 |
Financial Efficiency
Return on equity (ROE) is -21.13% and return on invested capital (ROIC) is -14.80%.
| Return on Equity (ROE) | -21.13% |
| Return on Assets (ROA) | -13.81% |
| Return on Invested Capital (ROIC) | -14.80% |
| Return on Capital Employed (ROCE) | -13.94% |
| Revenue Per Employee | 20,751 |
| Profits Per Employee | -357,098 |
| Employee Count | 335 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.81% |
| 50-Day Moving Average | 577.51 |
| 200-Day Moving Average | 755.98 |
| Relative Strength Index (RSI) | 36.18 |
| Average Volume (20 Days) | 19,029 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of GBP 6.95 million and -119.63 million in losses. Loss per share was -1.80.
| Revenue | 6.95M |
| Gross Profit | 6.08M |
| Operating Income | -140.72M |
| Pretax Income | -120.14M |
| Net Income | -119.63M |
| EBITDA | -139.55M |
| EBIT | -140.72M |
| Loss Per Share | -1.80 |
Balance Sheet
The company has 912.16 million in cash and 43.44 million in debt, giving a net cash position of 959.60 million.
| Cash & Cash Equivalents | 912.16M |
| Total Debt | 43.44M |
| Net Cash | 959.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 955.48M |
| Book Value Per Share | 13.52 |
| Working Capital | 900.87M |
Cash Flow
In the last 12 months, operating cash flow was -103.22 million and capital expenditures -1.11 million, giving a free cash flow of -104.33 million.
| Operating Cash Flow | -103.22M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | -104.33M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 87.44% |
| Operating Margin | -2,024.33% |
| Pretax Margin | -1,728.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.40% |
| Shareholder Yield | -17.40% |
| Earnings Yield | -3.63% |
| FCF Yield | -3.17% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 32.27.
| Altman Z-Score | 32.27 |
| Piotroski F-Score | n/a |